Chemoprevention of prostate cancer with nutrients and supplements

Area of Science:

• Oncology
• Preventive Medicine
• Nutritional Science

Background:

• Prostate cancer (PCa) is a growing public health concern with increasing adult populations.
• Its commonality and slow progression make PCa an ideal target for chemoprevention strategies.
• Current preventive agents include 5 alpha-reductase inhibitors like finasteride and dutasteride.

Purpose of the Study:

• To review the potential of various chemopreventive agents in reducing prostate cancer risk.
• To evaluate the efficacy of selenium, alpha-tocopherol, isoflavones, lycopene, green tea polyphenols, calcium, and resveratrol.

Main Methods:

• Literature review of studies investigating chemopreventive agents for prostate cancer.
• Analysis of existing research on specific compounds including selenium, alpha-tocopherol, and lycopene.
• Consideration of factors contributing to inconsistent study findings, such as study design and dosage.

Main Results:

• Some studies show encouraging results for agents like selenium and lycopene in decreasing PCa risk.
• However, other studies report negative or inconclusive findings, highlighting inconsistencies.
• Factors such as study design, sample size, and dosage may explain these discrepancies.

Conclusions:

• Chemopreventive agents may benefit high-risk individuals, including those with high-grade prostatic intraepithelial neoplasia or elevated PSA levels.
• Larger randomized controlled trials are necessary to confirm efficacy and clinical utility.
• Physicians should be aware of these potential preventive options and consider investigating combinations of agents for synergistic effects.